An experimental oral drug called tavapadon improved "on" time for people with Parkinson's when added to levodopa, and it did so without increasing troublesome dyskinesia in its main Phase 3 trial. It is not yet a treatment you can get: AbbVie submitted the drug to the FDA in September 2025, and it remains under review. Tavapadon is a once-daily pill that targets specific dopamine receptors. This article explains what the trial actually showed, what "fewer complications" means, and why the drug is still investigational.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What tavapadon is and how it differs from other Parkinson's drugs
- What the TEMPO-3 trial actually showed
- What "fewer complications" really means
- The limits of the evidence so far
- What this means for you right now
- Frequently Asked Questions
What tavapadon is and how it differs from other Parkinson's drugs
Tavapadon is an oral, once-daily selective dopamine D1/D5 receptor **partial** agonist developed by AbbVie. A dopamine agonist mimics dopamine, the brain chemical that is depleted in Parkinson's; "partial" means it activates receptors more gently than a full agonist. Most older dopamine agonists act on D2/D3 receptors, which are linked to side effects such as sleepiness, impulse-control problems, and swelling.
Tavapadon instead focuses on the D1/D5 receptor family. That selectivity is the mechanical reason researchers hoped for a cleaner side-effect profile. Importantly, tavapadon is a pill taken alongside levodopa, the standard Parkinson's medication. It is designed to smooth out symptom control, not to replace levodopa.
What the TEMPO-3 trial actually showed
The evidence behind the headline comes from TEMPO-3, a Phase 3 trial that added tavapadon to existing levodopa therapy. According to AbbVie's topline results, tavapadon increased total "on" time without troublesome dyskinesia by 1.7 hours versus 0.6 hours for placebo — a placebo-adjusted gain of 1.1 hours per day. "On" time is when medication is working and symptoms are controlled.
"Off" time is when symptoms return between doses. The same trial cut daily "off" time by 0.94 hours versus placebo, which points to fewer motor fluctuations. The trial enrolled 507 adults aged 40 to 80 who had been on levodopa for at least four weeks, per a NeurologyLive summary. They were randomized evenly to tavapadon 5–15 mg once daily or placebo.
What "fewer complications" really means
The "fewer complications" framing rests on one specific detail: the key endpoint measured "on" time *without troublesome dyskinesia*. Dyskinesia refers to the involuntary writhing or fidgeting movements that can develop after years of levodopa use. Gaining good "on" time without worsening those movements is the claimed advantage.
That result is meaningful, but it has a limit worth understanding. The reduced-side-effect idea from D1/D5 selectivity is a hypothesis, and the trial data do not establish head-to-head safety superiority over other drugs. In plain terms: tavapadon beat a placebo. It was not tested against other levodopa-enhancing therapies, so no one can yet say it causes fewer complications than existing add-on options.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
The limits of the evidence so far
Readers should weigh a few caveats before treating this as a settled breakthrough. As Practical Neurology notes, TEMPO-3 was a placebo-controlled adjunct trial, not a comparison against active therapies, and long-term real-world outcomes are not yet demonstrated.
One point of confusion to avoid: tavapadon is not Vyalev. Vyalev (foscarbidopa/foslevodopa) was FDA-approved in October 2024 for advanced Parkinson's, but it is a continuous infusion, not the oral pill discussed here.
- The trial ran for a defined study period, so durability of benefit is unknown.
- Participants were 40 to 80 and already on levodopa; results may not apply to newly diagnosed or much older patients.
- Safety over years of use has not been shown.
- No pricing or availability exists yet, because the drug is not approved.
What this means for you right now
If tavapadon is approved — a decision is expected in 2026 — it would give people with motor fluctuations another oral option to add to levodopa. Until then, it is investigational and cannot be prescribed. Here is what you can practically do: Because tavapadon is under FDA review, the most reliable updates will come from your care team and the trial registry rather than from press coverage.
- Do not change or stop any current medication based on this news.
- If your "off" time or dyskinesia is a growing problem, raise it with your neurologist now; approved options already exist.
- Ask whether a clinical trial fits your situation. You can review the TEMPO-3 trial listing on ClinicalTrials.gov.
- Keep a simple daily log of "on" and "off" periods to bring to appointments.
Frequently Asked Questions
Can I get tavapadon from my doctor now?
No. It is under FDA review after AbbVie's September 2025 submission and cannot be prescribed until a decision, expected in 2026.
Does tavapadon replace levodopa?
No. It was studied as an add-on to levodopa to extend good "on" time and reduce "off" time, not as a standalone therapy.
How much extra "on" time did it provide?
In TEMPO-3, it added 1.7 hours of "on" time without troublesome dyskinesia versus 0.6 hours for placebo—a 1.1-hour placebo-adjusted gain.
You Might Also Like
- Parkinson’s Treatment Breakthrough: Novel Drug Amplifies Levodopa Results With Fewer Complications
- Personalized stem cell treatment for Parkinson’s: New research shows promising clinical results
- Parkinson’s Treatment State-by-State Guide: Rules Deadlines and Local Impact Explained